Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

37.34
+0.53001.44%
Post-market: 37.21-0.1287-0.34%19:53 EDT
Volume:4.30M
Turnover:160.85M
Market Cap:43.50B
PE:62.23
High:37.75
Open:36.79
Low:36.65
Close:36.81
52wk High:37.83
52wk Low:17.82
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.87
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.61
PE(LYR):30.86

Loading ...

Earning Preview: Teva Pharmaceutical this quarter’s revenue is expected to decrease by 4.49%, and institutional views are bullish

Earnings Agent
·
Apr 23

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 21

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch

Simply Wall St.
·
Apr 19

US appeals court revives Teva lawsuit against Eli Lilly over migraine drug

Reuters
·
Apr 16

Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)?

Simply Wall St.
·
Apr 13

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Apr 10

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

BofA Adjusts Price Target on Teva Pharmaceutical Industries to $42 From $38, Maintains Buy Rating

MT Newswires Live
·
Apr 09

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones

Simply Wall St.
·
Apr 04

Teva’s New Biosimilars Test Growth Plan And Earnings Reshaping Potential

Simply Wall St.
·
Mar 31

Teva call volume above normal and directionally bullish

TIPRANKS
·
Mar 31

Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 30

How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases

Simply Wall St.
·
Mar 26

Scotiabank Remains a Buy on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 25

Enphase, AST SpaceMobile, AppLovin, ConocoPhillips, Teva Shock

TIPRANKS
·
Mar 21

Barclays Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 20

Top Teva Executive Makes Major Stock Move That Investors Can’t Ignore

TIPRANKS
·
Mar 20

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue

Simply Wall St.
·
Mar 17

J.P. Morgan Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 05

Teva Pharmaceuticals Price Target Raised to $41.00/Share From $40.00 by Piper Sandler

Dow Jones
·
Mar 04